Trial · NCT02959411
Tolvaptan for Advanced or Refractory Heart Failure
NCT02959411, Phase 4, Terminated, University of Calgary
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Tolvaptan for Advanced or Refractory Heart Failure. Trials, record NCT02959411. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02959411
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Tolvaptan for Advanced or Refractory Heart Failure
- NCT number
- NCT02959411
- Status
- Terminated
- Phases
- Phase 4
- Enrollment
- 9 participants, actual
- Lead sponsor
- University of Calgary
- Conditions
- Heart Failure, Hyponatremia
- Interventions
- Tolvaptan, Standard of care diuretic therapy
- First posted
- 2016-11-09
- Last updated
- 2020-07-27
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in body weight | From randomization to 96 hours after randomization | |
| Secondary | Total 96 hour urine output | From randomization to 96 hours post randomization | Measured in ml urine |
| Secondary | Subjective change in shortness of breath | 48 hours after randomization and 96 hours post randomization | As assessed by a 5 point Likert scale |
| Secondary | Change in renal function | From randomization to 7 days post randomization | Measured by estimated glomerular filtration rate |
| Secondary | Proportion of patients developing worsening renal function (WRF) | From randomization to 7 days post randomization | Categorical measure- need for renal replacement therapy or ultrafiltration or increase in serum creatinine by \> 26 umol/L |
| Secondary | Change in serum sodium | From randomization to 7 days post randomization | Measured in mmol/L |
| Secondary | Length of hospitalization | From hospital admission to 30 days post randomization | Number of days in hospital |
| Secondary | Need for intensive care unit admission | From hospital admission to 30 days post randomization | Categorical measure (yes/no) |
| Secondary | Need for positive inotropic agent use | From randomization to 7 days post randomization | Categorical measure (yes/no) |
| Secondary | Composite of Worsening Renal Function or need for inotropic agent | From randomization to 7 days post randomization | Worsening Renal Function defined as increase from serum creatinine at randomization of more than 30 umol/L at any time from randomization to 7 days. This is a categorical outcome (yes/no) |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02959411
GET https://conductscience.org/api/trials/v1/NCT02959411/registered